Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
taspoglutide · 10 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| placebo | PLACEBO_COMPARATOR | - |
| taspoglutide | EXPERIMENTAL | - |
| pioglitazone | ACTIVE_COMPARATOR | - |
| taspoglutide 10mg | EXPERIMENTAL | taspoglutide 10mg sc weekly |
| taspoglutide 10mg/20mg | EXPERIMENTAL | taspoglutide 20mg sc weekly after 4 weeks of taspoglutide 10mg sc weekly |
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | PLACEBO_COMPARATOR | - |
| insulin glargine | ACTIVE_COMPARATOR | insulin glargine starting dose 10 IU daily in addition to continued prestudy metformin treatment |
| taspoglutide 10 mg | EXPERIMENTAL | taspoglutide 10 mg once weekly in addition to continued prestudy metformin treatment |
| taspoglutide 10 mg/20 mg | EXPERIMENTAL | taspoglutide 20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly) in addition to continued prestudy metformin treatment |
| taspoglutide 10mg sc | EXPERIMENTAL | - |
| taspoglutide 10mg/20mg sc | EXPERIMENTAL | - |
| Taspoglutide 20mg | EXPERIMENTAL | sc weekly |
| Taspoglutide 20mg-30mg | EXPERIMENTAL | sc weekly |
| Taspoglutide 20mg-40mg | EXPERIMENTAL | sc weekly |
| 4 | EXPERIMENTAL | - |
| 5 | EXPERIMENTAL | - |
| 6 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| placebo | DRUG | sc weekly |
| taspoglutide | DRUG | 10 mg sc weekly for 4 weeks, followed by 20 mg sc weekly |
| pioglitazone | DRUG | 30mg po once daily for 4 weeks, followed by 45mg once daily |
| insulin glargine | DRUG | starting dose 10 IU daily |
| metformin | DRUG | As prescribed |
| Taspoglutide 20mg | DRUG | sc weekly |
| Taspoglutide 20mg-30mg | DRUG | sc weekly |
| Taspoglutide 20mg-40mg | DRUG | sc weekly |
Inclusion Criteria: * adult patients, \>18 years of age * diabetes mellitus type 2 * HbA1c \>/=6.5% and \</=10% at screening * BMI \>/=23kg/m2 * cardiovascular disease with onset \>/=1 month prior to screening Exclusion Criteria: * diagnosis or history of type 1 diabetes or secondary forms of dia...
Taspoglutide is an investigational drug being developed for the treatment of Type 2 Diabetes Mellitus. It is a small molecule that has been studied in clinical trials for its effects on glycemic control in patients with this condition.
Taspoglutide is being developed by Roche Holding AG, a company publicly traded under the ticker symbol RHHBY. The drug has been studied in clinical trials sponsored by the company.
Taspoglutide has reached Phase 3 clinical development. However, all clinical trials for the drug are completed, with no active trials currently ongoing. It remains an investigational agent and has not been approved by regulatory authorities.
Taspoglutide has been studied in multiple clinical trials, including NCT00423501, NCT00460941, NCT00809705, and NCT00811460. These trials have investigated its use in Type 2 Diabetes Mellitus, with a total enrollment of 5467 participants across all studies.
Taspoglutide is described as a GLP-1 analogue in clinical trial titles. It has been studied for its effects on gastric emptying and glycemic control in patients with Type 2 Diabetes Mellitus, consistent with the mechanism of GLP-1 receptor agonists.